

Imanol Arozarena

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/645505/publications.pdf>

Version: 2024-02-01

32
papers

2,391
citations

304368

22
h-index

433756

31
g-index

32
all docs

32
docs citations

32
times ranked

4385
citing authors

#	ARTICLE	IF	CITATIONS
1	Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus. <i>Pancreatology</i> , 2021, 21, 215-223.	0.5	2
2	Understanding the Molecular Mechanism of miR-877-3p Could Provide Potential Biomarkers and Therapeutic Targets in Squamous Cell Carcinoma of the Cervix. <i>Cancers</i> , 2021, 13, 1739.	1.7	4
3	Identification of a Dexamethasone Mediated Radioprotection Mechanism Reveals New Therapeutic Vulnerabilities in Glioblastoma. <i>Cancers</i> , 2021, 13, 361.	1.7	8
4	Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11656.	1.8	3
5	Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?. <i>Cancers</i> , 2021, 13, 5799.	1.7	18
6	Cooperative behaviour and phenotype plasticity evolve during melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 695-708.	1.5	18
7	Phenotype plasticity as enabler of melanoma progression and therapy resistance. <i>Nature Reviews Cancer</i> , 2019, 19, 377-391.	12.8	262
8	RAS at the Golgi antagonizes malignant transformation through PTPR β -mediated inhibition of ERK activation. <i>Nature Communications</i> , 2018, 9, 3595.	5.8	18
9	Targeting invasive properties of melanoma cells. <i>FEBS Journal</i> , 2017, 284, 2148-2162.	2.2	36
10	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710.	4.2	71
11	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	2.9	220
12	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	3.3	63
13	Overcoming resistance to BRAF inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 387-387.	0.7	109
14	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	0.7	0
15	Glucose availability controls ATF4-mediated MITF suppression to drive melanoma cell growth. <i>Oncotarget</i> , 2017, 8, 32946-32959.	0.8	46
16	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 33.	1.8	84
17	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	7.7	198
18	Targeting MITF in the tolerance-phase. <i>Oncotarget</i> , 2016, 7, 54094-54095.	0.8	4

#	ARTICLE	IF	CITATIONS
19	MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1236-1246.	1.9	36
20	Microphthalmia-associated transcription factor in melanoma development and MAP kinase pathway targeted therapy. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 390-406.	1.5	168
21	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. <i>Molecular Cancer</i> , 2014, 13, 154.	7.9	2
22	Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 33-46.	3.0	85
23	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A. <i>Cancer Cell</i> , 2011, 19, 45-57.	7.7	190
24	Ras, an Actor on Many Stages: Posttranslational Modifications, Localization, and Site-Specified Events. <i>Genes and Cancer</i> , 2011, 2, 182-194.	0.6	49
25	Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins. <i>Molecular and Cellular Biology</i> , 2009, 29, 1338-1353.	1.1	100
26	FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKC ϵ , B-Raf and S6K2. <i>EMBO Journal</i> , 2006, 25, 3078-3088.	3.5	173
27	Distinct Utilization of Effectors and Biological Outcomes Resulting from Site-Specific Ras Activation: Ras Functions in Lipid Rafts and Golgi Complex Are Dispensable for Proliferation and Transformation. <i>Molecular and Cellular Biology</i> , 2006, 26, 100-116.	1.1	110
28	Activation of H-Ras in the Endoplasmic Reticulum by the RasGRF Family Guanine Nucleotide Exchange Factors. <i>Molecular and Cellular Biology</i> , 2004, 24, 1516-1530.	1.1	87
29	Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization. <i>Journal of Biological Chemistry</i> , 2003, 278, 4572-4581.	1.6	102
30	Maintenance of Cdc42 GDP-bound State by Rho-GDI Inhibits MAP Kinase Activation by the Exchange Factor Ras-GRF. <i>Journal of Biological Chemistry</i> , 2001, 276, 21878-21884.	1.6	32
31	H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. <i>Oncogene</i> , 2000, 19, 783-790.	2.6	53
32	The Rho Family GTPase Cdc42 Regulates the Activation of Ras/MAP Kinase by the Exchange Factor Ras-GRF. <i>Journal of Biological Chemistry</i> , 2000, 275, 26441-26448.	1.6	40